Two Sigma Advisers
ACRS icon

Two Sigma Advisers’s Aclaris Therapeutics ACRS Stock Holding History

Two Sigma Advisers’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-255,400
Closed -$769K – 29
2025
Q4 		$769K Sell
255,400
-94,700
-27% -$239K ﹤0.01% 1613
2025
Q3 		$665K Sell
350,100
-414,200
-54% -$722K ﹤0.01% 1646
2025
Q2 		$1.09M Sell
764,300
-94,100
-11% -$127K ﹤0.01% 1398
2025
Q1 		$1.31M Sell
858,400
-119,000
-12% -$254K ﹤0.01% 1340
2024
Q4 		$2.42M Sell
977,400
-324,100
-25% -$806K 0.01% 1030
2024
Q3 		$1.5M Sell
1,301,500
-135,400
-9% -$166K ﹤0.01% 1228
2024
Q2 		$1.58M Sell
1,436,900
-14,200
-1% -$16.7K ﹤0.01% 1319
2024
Q1 		$1.8M Buy
1,451,100
+30,100
+2% +$35.9K ﹤0.01% 1286
2023
Q4 		$1.49M Buy
1,421,000
+1,275,000
+873% +$3.89M ﹤0.01% 1440
2023
Q3 		$1M Buy
146,000
+121,700
+501% +$1.04M ﹤0.01% 1519
2023
Q2 		$252K Sell
24,300
-16,200
-40% -$147K ﹤0.01% 2035
2023
Q1 		$328K Buy
+40,500
New +$514K ﹤0.01% 2107
2022
Q1 		– Sell
-13,300
Closed -$193K – 2715
2021
Q4 		$193K Sell
13,300
-3,100
-19% -$47K ﹤0.01% 2296
2021
Q3 		$295K Sell
16,400
-56,800
-78% -$911K ﹤0.01% 2125
2021
Q2 		$1.28M Buy
73,200
+12,900
+21% +$293K ﹤0.01% 1519
2021
Q1 		$1.52M Buy
60,300
+13,100
+28% +$256K ﹤0.01% 1409
2020
Q4 		$305K Buy
47,200
+24,000
+103% +$101K ﹤0.01% 2038
2020
Q3 		$60K Sell
23,200
-2,700
-10% -$6.04K ﹤0.01% 2311
2020
Q2 		$42K Sell
25,900
-8,800
-25% -$11.8K ﹤0.01% 2436
2020
Q1 		$36K Sell
34,700
-23,200
-40% -$31.6K ﹤0.01% 2393
2019
Q4 		$109K Sell
57,900
-97,100
-63% -$161K ﹤0.01% 2245
2019
Q3 		$167K Buy
+155,000
New +$220K ﹤0.01% 2072

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Two Sigma Advisers's ACRS Position: Q1 2026 in Review

Two Sigma Advisers sold out of Aclaris Therapeutics (ACRS) in Q1 2026, closing a stake of 255,400 shares — an estimated $769K sold.

Two Sigma Advisers first reported a position in ACRS in Q3 2019 and held it in 22 quarters. The position peaked at $2.42M in Q4 2024. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Two Sigma Advisers reported no remaining Aclaris Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 255,400 Aclaris Therapeutics shares in Q1 2026, an estimated $769K.
  • Two Sigma Advisers first reported a position in Aclaris Therapeutics in Q3 2019 and held it in 22 quarters.
  • Two Sigma Advisers's Aclaris Therapeutics position peaked at $2.42M in Q4 2024.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.